In their recent editorial, Rao and Nolan (1) decided to ignore the well-known relationship among experience, volume, and medical outcomes and played the dangerous game of rejecting an important hazard signal that, if tackled properly, could better the outcomes of patients undergoing heart catheterization.
Our data demonstrated an increase in the rate of femoral vascular access-site complications (VASCs) after the widespread adoption of radial access (RA) that persisted after multivariate adjustment. This increase in femoral access (FA)-related VASCs was numerically so relevant that it offset the benefit of RA at the overall population level. We concluded that approximately one-half of VASCs occurring in patients undergoing FA are attributable to the adoption of RA (2) . However, Rao and Nolan went so far as to ascribe a causality dimension to attributable fractions ("by using the term attributable, the authors imply causation-that the radial approach caused femoral complications" [1] ). Their statistical faux pas translates a defective understanding of the concept of population attributable fraction (PAF), which is defined as the proportional reduction in average disease risk over a specified time interval Please note: Dr. Jolicoeur is supported by research grants from Fonds de Recherche du Québec en Santé, the Canadian Institutes for Health Research, and by La Fondation de l'Institut de Cardiologie de Montréal. Dr. Azzalini has reported that he has no relationships relevant to the contents of this paper to disclose. 
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DCB and Dissections
In Search of a Good Balance Between
Enthusiasm and Scientific Strictness
Byrne and Joner (1) recently wrote an elegant editorial comment on a study that our group recently published in JACC: Cardiovascular Interventions (2).
We have to thank the 2 experts for their kind words regarding the importance of this type of proof of concept, independent study. However, while reading the editorial, we made several observations that may be of some help for future discussions, which we summarize in the following points:
First, despite their enthusiasm for stents, Byrne and Joner (1) should have also mentioned one of the major drawbacks of this technology, namely, the risk of very late (and never-ending) stent thrombosis. This concern has been shown to be a serious issue indeed, both for first-generation and (to a lesser extent) second-generation drug-eluting stents. In conclusion, we are well aware of the limitations of our study and we concur that stronger scientific evidence is required before a change in clinical practice may be recommended. However, we strongly believe that small, independent, well-designed pilot studies are necessary to advance the field and draw the line for additional larger studies able to provide definitive clinical evidence. Please note: Both authors have reported that they have no relationships relevant to the contents of this paper to disclose.
